IntelliCell Biosciences Announces the Addition of Mr. Sam Khashman to Board of Directors
October 18 2013 - 8:57AM
Marketwired
IntelliCell Biosciences Announces the Addition of Mr. Sam Khashman
to Board of Directors
NEW YORK, NY--(Marketwired - Oct 18, 2013) - IntelliCell
Biosciences, Inc. (OTCQB: SVFC), a regenerative medicine company
utilizing adult autologous vascular fraction cells (SVFCs) derived
from the blood vessels in lipoaspirate, announced today the
addition of Mr. Sam Khashman to the company's Board of
Directors.
During the past 20 years, Mr. Khashman has successfully directed
the creation and launch of 14 products and 3 companies in the
healthcare, financial, and manufacturing sector. He currently
serves as the President and Chief Executive Officer of Technology
Partners, Inc. DBA IMAGINE Software. Mr. Khashman founded the
company and created the IMAGINE practice management system that is
currently used in 48 States by more than 10,000 physicians. In
addition to his involvement in numerous civic and charitable
organizations, Mr. Khashman serves on the board of the National
Chamber Foundation, the public policy think tank of the U.S.
Chamber of Commerce in Washington D.C. A native of Germany,
Khashman graduated from both the University of Lüneburg and the
University of North Carolina.
"We are honored to have Mr. Sam Khashman join our Board of
Directors and look forward to leveraging his tremendous knowledge
of the medical field, most notably in healthcare reimbursements,"
stated Dr. Steven Victor, Chairman and Chief Executive Officer of
IntelliCell Biosciences. "Management believes that under the
new Obamacare Program the IntelliCell Cellular Therapy will become
a reimbursable medical cost. Mr. Khashman's expertise and
longstanding industry relationships will allow us to navigate both
current and future health care programs, as we expand our roster of
patients that will now be able to receive reimbursements for their
cellular therapy treatments."
About IntelliCell Biosciences IntelliCell is a pioneering
regenerative medicine company focused on the expanding regenerative
medical markets using adult autologous stromal vascular fraction
cells (SVFCs) derived from the blood vessels in the adult adipose
tissue. IntelliCell Biosciences has developed its own patented
technology and protocol to separate adult autologous vascular cells
from adipose tissue without the use of enzymes. One of the revenue
streams IntelliCell is pursuing is placing its labs into Hospitals
and Ambulatory Surgical Centers. IntelliCell will also be seeking
to develop technology-licensing agreements with technology
developers, universities, and international business entities.
Forward-Looking Statements Certain statements set forth in this
press release constitute "forward-looking statements."
Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning," "expect," "believe," "will likely," "will reach," "will
change," "will soon," "should," "could," "would," "may," "can" or
words or expressions of similar meaning. Such statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and
financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve
risks and uncertainties, including those relating to the Company's
ability to grow its business. Actual results may differ materially
from the results predicted and reported results should not be
considered as an indication of future performance. The potential
risks and uncertainties include, among others, the Company's
limited operating history, the limited financial resources,
domestic or global economic conditions, activities of competitors
and the presence of new or additional competition, and changes in
Federal or State laws. More information about the potential factors
that could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact Investors: Chris Camarra Alliance Advisors, LLC Email
Contact